http://xmrrwallet.com/cmx.pbit.ly/4cT4mTK We are pleased to announce that we have completed our Series E funding round. These funds will help advance our clinical trial, utilizing ST266 to treat Necrotizing Enterocolitis (NEC). NEC is a devastating disease, affecting many pre-mature babies. Thank you, Eric Keller, Pat Welch, Ronald Poropatich, MD, MS, and our amazing current investors.
Congratulations Noveome Biotherapeutics, Inc. and Eric Keller on closing their Series E! Not only will this allow for the advancement of clinical trials for their candidate for treating necrotizing enterocolitis in premature infants, it will also fuel development of manufacturing infrastructure right here in Pittsburgh. Regional Industrial Development Corporation (RIDC) via Paul J. Gough Pittsburgh Business Times https://xmrrwallet.com/cmx.plnkd.in/eYj5eUaw